医学
观察研究
置信区间
心源性休克
危险系数
优势比
内科学
重症监护室
肺动脉导管
荟萃分析
心脏病学
随机对照试验
相对风险
败血症
重症监护
重症监护医学
肺动脉
比例危险模型
队列研究
休克(循环)
临床试验
流行病学
肱动脉
导管
急诊医学
死亡风险
外科
死亡率
梅德林
生存分析
作者
Jorge Arturo Ortega-Hernandez,Francisco Chacón-Lozsán,L. Baldetti,Guglielmo Gallone,Pier Paolo Bocchino,Giulio Cacioli,Héctor González‐Pacheco,Jaime Hernandez-Montfort,Alexandra Arias‐Mendoza
出处
期刊:Shock
[Lippincott Williams & Wilkins]
日期:2026-01-27
卷期号:65 (4): 648-659
被引量:3
标识
DOI:10.1097/shk.0000000000002784
摘要
INTRODUCTION: The role of pulmonary artery catheterization (PAC) in cardiogenic shock (CS) remains debated: prior intensive care unit trials showed no benefit, but contemporary observational registries suggest improved outcomes. However, the overall evidence remains fragmented, with inconsistent phenotypic and outcome reporting. Our objective was to assess the association between PAC use and clinical outcomes in CS. METHODS: We systematically searched MEDLINE, Cochrane, and Scopus (2015-2025) for observational and registry studies in adult CS. Outcomes included in-hospital/30-day mortality, mechanical circulatory support (MCS), and sepsis. Pooled odds ratios (OR) and hazard ratios were estimated using random-effects models. Subgroup, meta-regression, and trial sequential analysis were performed. RESULTS: Fourteen observational studies (n = 789,553; 271,305 deaths) were included. Overall mortality averaged 34%. PAC use was associated with lower mortality (OR 0.70, 95% confidence interval [CI] 0.63-0.78; P < 0.001) with consistent benefit across CS phenotypes, although substantial heterogeneity was present (I² > 90%). Time-to-event analyses (7 studies, n = 5,142) confirmed a 32% relative hazard ratio (0.68, 95% CI 0.60-0.77; I² = 34%). PAC use was also linked to higher MCS initiation (OR 2.76, 95% CI 1.82-4.20; P < 0.001), with evidence of publication bias (Egger P = 0.0057) and an adjusted OR 3.98 after trim-and-fill. In addition, PAC was associated with increased sepsis risk (OR 1.83, 95% CI 1.42-2.35; I² = 61%). CONCLUSIONS: PAC use was consistently associated with improved survival across CS, and higher MCS use was associated with increased sepsis risk. Our findings support systematic PAC use as a therapeutic enabler in CS and should inform protocols and future randomized clinical trials design.
科研通智能强力驱动
Strongly Powered by AbleSci AI